Full-Time

ABCIA Commercial Operations Lead

Global Commercial Development

Posted on 8/28/2025

CSL

CSL

10,001+ employees

Develops and delivers biotherapies and vaccines

No salary listed

King of Prussia, PA, USA

Hybrid

Hybrid role requiring some in-office presence.

Category
Business & Strategy (2)
,
Required Skills
Communications
Requirements
  • Bachelor’s degree in business, life sciences, operations, or related field; MBA preferred
  • 10+ years of progressive experience in cross-functional roles, ideally within life sciences or healthcare
  • Strong business acumen and ability to translate strategic priorities into operational outcomes
  • Proven experience managing complex programs or projects in a fast-paced, matrixed environment
  • Trusted advisor to senior leaders, with executive presence and strong influencing skills
  • Demonstrated ability to organize, lead, and execute across diverse teams and initiatives
  • Exceptional communication skills, with experience crafting and delivering executive-level reporting and presentations
  • Strong interpersonal skills and emotional intelligence, with the ability to foster collaboration across global teams
  • Proficiency with digital tools and technologies that enhance team collaboration, tracking, and communication
  • Data-driven, innovative problem solver who drives process simplification and continuous improvement
Responsibilities
  • Support the VP, Global Commercial Development Hematology, by advancing cross-therapeutic area initiatives within Global Commercial Development
  • Serve as a trusted advisor and strategic partner to the SVP, ABCIA and ABCIA Leadership Team, providing insights on functional priorities, organizational risks, and cross-functional alignment
  • Lead annual strategic planning efforts, aligning objectives with enterprise goals and identifying opportunities for synergies, efficiencies, and resource optimization
  • Oversee budget planning and management, facilitating transparency and alignment with ABCIA and enterprise priorities
  • Support long-term planning for organizational evolution and operational refinement
  • Coordinate and standardize governance processes across key decision-making forums to ensure structured preparation and follow-through
  • Identify and implement continuous improvement initiatives using data and insights to drive efficiency
  • Lead and optimize weekly ABCIA LT meetings, including agenda development, topic prioritization, and follow-up on key actions
  • Track progress toward strategic goals and KPIs, ensuring timely and clear reporting to CSL Behring leadership
  • Drive consistency in processes such as goal setting, budget tracking, and talent development in collaboration with Finance, HR, and other partners
  • Support the preparation and delivery of management presentations, strategic updates, and executive reports (e.g., BoD requests, CSLB LT updates)
  • Act as a liaison between the SVP, ABCIA, ABCIA LT, and CSL Behring leadership, ensuring effective communication and functional alignment
  • Coordinate internal and external stakeholder engagements, partnering with Communications, HR, and other teams as needed
  • Develop and execute monthly ABCIA town halls, crafting compelling content and aligning leadership messaging
  • Maintain a master calendar of ABCIA meetings and milestones, ensuring integration with key Commercial and R&D activities
  • Bridge communication and collaboration gaps across ABCIA, enhancing alignment between Commercial, Medical, Market Access, and enterprise functions
  • Partner with the VP, Hematology, to support cross-TA global commercial development initiatives, ensuring alignment with broader commercial and enterprise strategies
  • Lead or support high-priority, cross-functional projects, ensuring strategic alignment and measurable outcomes
  • Identify and mitigate operational risks, escalating barriers to execution when needed
  • Apply change management and organizational effectiveness approaches to enhance team collaboration and performance

CSL is a global biotechnology company that develops and delivers biotherapies and influenza vaccines. It focuses on plasma-derived and recombinant therapies for rare and serious diseases and sells to healthcare providers, hospitals, and governments across the Americas, Asia Pacific, and Europe. Its product range includes treatments for rare diseases, influenza vaccines, and antivenoms, produced through its R&D, manufacturing, and distribution operations. CSL differentiates itself by offering the broadest portfolio of plasma-derived and recombinant therapies and by leveraging its global footprint and emphasis on diversity to reach diverse markets. The company’s main goal is to save lives and protect health by expanding access to high-quality therapies and vaccines worldwide.

Company Size

10,001+

Company Stage

IPO

Headquarters

Parkville, Australia

Founded

1916

Simplify Jobs

Simplify's Take

What believers are saying

  • HEMGENIX gene therapy sustains 37% factor IX levels through four years post-2025 data.
  • KOSTAIVE self-amplifying mRNA COVID vaccine approved by EC February 2025.
  • VarmX $2.2B acquisition option expands bleeding disorder pipeline in 2026.

What critics are saying

  • Seqirus separation triggers $500M charges and 14% revenue loss from Pentagon mandate scrap.
  • Grifols opens 20 plasma centers by 2027, eroding CSL Behring's immunoglobulin share.
  • Novartis Fabhalta displaces CSL Vifor's $1.5B nephrology revenues within 12 months.

What makes CSL unique

  • CSL Behring leads plasma-derived therapies for haemophilia and immunodeficiencies.
  • CSL Seqirus dominates influenza vaccines with global production scale.
  • CSL Vifor specializes in iron deficiency and nephrology treatments post-2022 acquisition.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Time Off

Paid Vacation

Paid Sick Leave

Paid Holidays

Company News

USA Herald
Sep 16th, 2025
CSL to Acquire VarmX in $2.2B Biotech Breakthrough Deal - USA Herald

In a high-stakes move that could reshape emergency medicine, global biotech giant CSL has struck an exclusive option agreement to acquire VarmX, a Netherlands-based biotech, in a deal valued at up to $2.2 billion. The announcement, made Tuesday by EQT Life Sciences, which counts VarmX in its portfolio, underscores just how valuable the Dutch company’s CSL to acquire VarmX in a $2.2B deal, backing breakthrough bleeding drug VMX-C001 with full trial funding.

CSL
Sep 16th, 2025
CSL Limited Celebrates 25 Years on the ASX

Global biotechnology leader, CSL, celebrated the Company’s 25th Anniversary of listing on the Australian Securities Exchange (ASX), commemorating the occasion with a ceremonial bell ring at...

Stock Titan
Aug 1st, 2025
Automated Logic Acquires Control Solutions Ltd.

Automated Logic – Canada, Ltd. (ALC), part of Carrier Global Corporation, has acquired Control Solutions, Ltd. (CSL), an independent provider of building-automation systems in Coquitlam, British Columbia. This acquisition establishes ALC's first field office in Vancouver, expanding its presence in Western Canada and enhancing its ability to deliver intelligent building solutions in high-growth sectors across British Columbia.

PharmiWeb.com
Apr 14th, 2025
First Patient Treated With Hemgenix® (Etranacogene Dezaparvovec) Gene Therapy For Haemophilia B In Austria

Vienna, Austria – 9 April 2025 - CSL Behring Austria today announced that the first haemophilia B patient in Austria was treated with the gene therapy HEMGENIX® (etranacogene dezaparvovec) at the Comprehensive Care Center of the University Hospital of Medicine Vienna.HEMGENIX® is the first one-time gene therapy approved in Europe for the treatment of adults with severe and moderately severe haemophilia B, an inherited bleeding disorder caused by the lack of Factor IX (a protein needed to produce blood clots to stop bleeding). It is used in adults without a history of Factor IX inhibitors.1“It is a great opportunity for people with hemophilia B to live a symptom-free life for many years,” explains hematologist Univ.-Prof. Priv.-Doz. Dr Cihan Ay from the Medical University of Vienna, University Clinic for Internal Medicine I Clinical Department for Hematology and Hemostaseology."For the community of affected patients and their families, this represents an enormously significant milestone: the ability to treat hemophilia with gene therapy, and the fact that this option is now available in Austria, is something our community has been eagerly anticipating and hoping for over decades," says Thomas Schindl, MA, Chairman of the Austrian Hemophilia Society (ÖHG)."We are proud and grateful to offer haemophilia B patients in Austria a treatment option that has the potential to transform their lives," said Dr Beate Natmessnig, Managing Director of CSL Behring Austria. "This achievement is the result of outstanding regional and national collaboration among all parties involved and is a strong testament to Austria's innovative capabilities."HEMGENIX® was granted conditional marketing authorisation by the European Commission (EC) for the European Union and European Economic Area in February 2023, following approval from the U.S. Food and Drug Administration (FDA) in November 2022

PharmiWeb.com
Apr 3rd, 2025
Csl Behring And Gkv-Spitzenverband Agree On Reimbursement Price For Hemgenix® – Europe'S First Gene Therapy For Haemophilia B

Marburg, Germany, 2 April 2025 – CSL Behring and the GKV-Spitzenverband (National Association of Statutory Health Insurance Funds) have successfully concluded negotiations on the reimbursement price of HEMGENIX®. This agreement marks the availability of the first gene therapy approved in Europe for haemophilia B under an innovative, national, success-based reimbursement model, being implemented for the first time in Germany.HEMGENIX® represents significant progress in the treatment of haemophilia B. The aim of this one-time gene therapy is to eliminate the need for regular factor IX infusions, thereby offering patients the possibility of more freedom from prophylaxis and significantly improving their quality of life.1-4 This development not only provides substantial relief for those affected but also has the potential to reduce long-term costs for the healthcare system.‘The performance-based payment model at national level which was agreed with the GKV-Spitzenverband is unique in Germany. It addresses key reimbursement challenges, such as the question of long-term efficacy, which is inherent for any one-time therapy. Reimbursement is linked to treatment success of the individual patient,’ explains Stefan Neudoerfer, CSL Behring's chief negotiator in Germany.Moreover, this reimbursement model reflects the high therapeutic and innovative value of HEMGENIX® and sets new standards for integrating innovative gene therapies into the German healthcare system.‘The agreement on the reimbursement price of HEMGENIX® is a decisive step for the care of people with haemophilia B in Germany. It enables access to a groundbreaking therapy and recognises the long-term medical and economic benefits of gene therapy,’ explains Christian Wieszner, Managing Director of CSL Behring Germany.With this agreement, CSL Behring is underlining its commitment to innovative therapies that sustainably improve the lives of patients

INACTIVE